Development of novel radiochemotherapy approaches targeting prostate tumor progenitor cells using nanohybrids

International Journal of Cancer

Volumn 137, Issue 10, 2015, Pages 2492-2503

  Castro Nava, Arturo ^a,b   Cojoc, Monica ^a   Peitzsch, Claudia ^a   Cirillo, Giuseppe ^c   Kurth, Ina ^a   Fuessel, Susanne ^a   Erdmann, Kati ^a   Kunhardt, David ^b   Vittorio, Orazio ^d,e   Hampel, Silke ^b   Dubrovska, Anna ^a,f  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b IFW DRESDEN   (Germany)

^c UNIVERSITY OF CALABRIA   (Italy)

^d CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

carbon nanotubes; catechin; radiosensitization; tumor initiating cells

Indexed keywords

ALDEHYDE DEHYDROGENASE; BETA CATENIN; CARBON NANOTUBE; CATECHIN; GELATIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOCOMPATIBILITY; CARDIAC STEM CELL; CELL POPULATION; CELL SURVIVAL; CELL VIABILITY; CHEMORADIOTHERAPY; CLONOGENESIS; CONJUGATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; ENZYME ACTIVITY; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE TUMOR; RADIOSENSITIVITY; X IRRADIATION; ANIMAL; CANCER STEM CELL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; DRUG FORMULATION; GENE EXPRESSION REGULATION; HUMAN; MALE; METABOLISM; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; RADIATION RESPONSE; SYNTHESIS; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS; CATECHIN; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMORADIOTHERAPY; DRUG COMPOUNDING; GELATIN; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; NANOTUBES, CARBON; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; RADIATION-SENSITIZING AGENTS;

EID: 84941944139     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29614     Document Type: Article

References (58)

1. Horwich A, Parker C, de Reijke T, Kataja V., Group EGW. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24(Suppl 6): vi106-114.
2. Cojoc M, Mabert K, Muders MH, Dubrovska A., A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms. Semin Cancer Biol 2015; 31: 16-27.
3. Peitzsch C, Kurth I, Kunz-Schughart L, Baumann M, Dubrovska A., Discovery of the cancer stem cell related determinants of radioresistance. Radiother Oncol 2013; 108: 378-87.
4. Rastogi V, Yadav P, Bhattacharya SS, et al., Carbon nanotubes: an emerging drug carrier for targeting cancer cells. J Drug Deliv 2014; 2014: 670815.
5. Drbohlavova J, Chomoucka J, Adam V, et al., Nanocarriers for anticancer drugs-new trends in nanomedicine. Curr Drug Metab 2013; 14: 547-64.
6. Danhier F, Feron O, Preat V., To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 2010; 148: 135-46.
7. Lacerda L, Russier J, Pastorin G, et al., Translocation mechanisms of chemically functionalised carbon nanotubes across plasma membranes. Biomaterials 2012; 33: 3334-43.
8. Maeda H, Wu J, Sawa T, et al., Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release 2000; 65: 271-84.
9. Wong BS, Yoong SL, Jagusiak A, et al., Carbon nanotubes for delivery of small molecule drugs. Adv Drug Deliv Rev 2013; 65: 1964-2015.
10. Weng CJ, Yen GC., Flavonoids, a ubiquitous dietary phenolic subclass, exert extensive in vitro anti-invasive and in vivo anti-metastatic activities. Cancer Metastasis Rev 2012; 31: 323-51.
11. Tang SN, Singh C, Nall D, et al., The dietary bioflavonoid quercetin synergizes with epigallocathechin gallate (EGCG) to inhibit prostate cancer stem cell characteristics, invasion, migration and epithelial-mesenchymal transition. J Mol Signal 2010; 5: 14.
12. Khan N, Bharali DJ, Adhami VM, et al., Oral administration of naturally occurring chitosan-based nanoformulated green tea polyphenol EGCG effectively inhibits prostate cancer cell growth in a xenograft model. Carcinogenesis 2014; 35: 415-23.
13. Manfred Ritschel AL, Dieter E, Steffen O, Bernd B., Rhenium-catalyzed growth carbon nanotubes. J Phys Chem C 2007; 111: 8414-7.
14. Tsai HC, Lin JY, Maryani F, et al., Drug-loading capacity and nuclear targeting of multiwalled carbon nanotubes grafted with anionic amphiphilic copolymers. Int J Nanomed 2013; 8: 4427-40.
15. Sharpe B, Beresford M, Bowen R, et al., Searching for prostate cancer stem cells: markers and methods. Stem Cell Rev 2013; 9: 721-30.
16. Lecumberri E, Dupertuis YM, Miralbell R, Pichard C., Green tea polyphenol epigallocatechin-3-gallate (EGCG) as adjuvant in cancer therapy. Clin Nutr 2013; 32: 894-03.
17. Vittorio O, Voliani V, Faraci P, et al., Magnetic catechin-dextran conjugate as targeted therapeutic for pancreatic tumour cells. J Drug Target 2014; 22: 408-15.
18. Cirillo G, Vittorio O, Hampel S, et al., Incorporation of carbon nanotubes into a gelatin-catechin conjugate: innovative approach for the preparation of anticancer materials. Int J Pharm 2013; 446: 176-82.
19. Vittorio O, Brandl MB, Cirillo G, et al., Novel functional cisplatin carrier based on carbon nanotubes-quercetin nanohybrid induces synergistic anticancer activity against neuroblastoma in vitro. RSC Adv 2014; 4: 31378-84.
20. Baumann M, Krause M, Hill R., Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008; 8: 545-54.
21. Dubrovska A, Kim S, Salamone RJ, et al., The role of PTEN/akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations. Proc Natl Acad Sci USA 2009; 106: 268-73.
22. Cojoc M, Peitzsch C, Kurth I, et al., Aldehyde dehydrogenase is regulated by Beta-catenin/TCF and promotes radioresistance in prostate cancer progenitor cells. Cancer Res 2015; 75: 1482-94.
23. Chiou SH, Wang ML, Chou YT, et al., Coexpression of oct4 and nanog enhances malignancy in lung adenocarcinoma by inducing cancer stem cell-like properties and epithelial-mesenchymal transdifferentiation. Cancer Res 2010; 70: 10433-44.
24. Kim Y, Kim KH, Lee J, et al., Wnt activation is implicated in glioblastoma radioresistance. Lab Invest 2012; 92: 466-73.
25. Iv Santaliz-Ruiz LE, Xie X, Old M, et al., Emerging role of nanog in tumorigenesis and cancer stem cells. Int J Cancer 2014; 135: 2741-8.
26. Schwartz DR, Wu R, Kardia SL, et al., Novel candidate targets of beta-catenin/T-cell factor signaling identified by gene expression profiling of ovarian endometrioid adenocarcinomas. Cancer Res 2003; 63: 2913-22.
27. Ray R, Cabal-Manzano R, Moser AR, et al., Up-regulation of fibroblast growth factor-binding protein, by beta-catenin during colon carcinogenesis. Cancer Res 2003; 63: 8085-9.
28. Yamashita T, Budhu A, Forgues M, Wang XW., Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 2007; 67: 10831-9.
29. Lin SY, Xia W, Wang JC, et al., Beta-catenin, a novel prognostic marker for breast cancer: its roles in cyclin d1 expression and cancer progression. Proc Natl Acad Sci U S A 2000; 97: 4262-6.
30. Rajasekhar VK, Studer L, Gerald W, et al., Tumour-initiating stem-like cells in human prostate cancer exhibit increased NF-kappaB signalling. Nat Commun 2011; 2: 162.
31. Kim YS, Farrar W, Colburn NH, Milner JA., Cancer stem cells: potential target for bioactive food components. J Nutr Biochem 2012; 23: 691-8.
32. Stefanska B, Karlic H, Varga F, et al., Epigenetic mechanisms in anti-cancer actions of bioactive food components-the implications in cancer prevention. Br J Pharmacol 2012; 167: 279-97.
33. Du GJ, Zhang Z, Wen XD, et al., Epigallocatechin gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients 2012; 4: 1679-91.
34. Yu Y, Deng Y, Lu BM, et al., Green tea catechins: a fresh flavor to anticancer therapy. Apoptosis 2014; 19: 1-18.
35. Suganuma M, Saha A, Fujiki H., New cancer treatment strategy using combination of green tea catechins and anticancer drugs. Cancer Sci 2011; 102: 317-23.
36. Alshatwi AA., Catechin hydrate suppresses MCF-7 proliferation through tp53/Caspase-mediated apoptosis. J Exp Clin Cancer Res 2010; 29: 167.
37. Gu JW, Makey KL, Tucker KB, et al., EGCG, a major green tea catechin suppresses breast tumor angiogenesis and growth via inhibiting the activation of HIF-1alpha and NFkappaB, and VEGF expression. Vascular Cell 2013; 5: 9.
38. Al-Hazzani AA, Alshatwi AA., Catechin hydrate inhibits proliferation and mediates apoptosis of SiHa human cervical cancer cells. Food Chem Toxicol 2011; 49: 3281-6.
39. Wang Y, Ho CT., Polyphenolic chemistry of tea and coffee: a century of progress. J Agric Food Chem 2009; 57: 8109-114.
40. Chow HH, Cai Y, Hakim IA, et al., Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003; 9: 3312-9.
41. Landis-Piwowar K, Chen D, Foldes R, et al., Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009-present). Exp Opin Ther Pat 2013; 23: 189-202.
42. Chen D, Wan SB, Yang H, et al., EGCG, green tea polyphenols and their synthetic analogs and prodrugs for human cancer prevention and treatment. Adv Clin Chem 2011; 53: 155-77.
43. Vittorio O, Cirillo G, Iemma F, et al., Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma. Pharm Res 2012; 29: 2601-14.
44. Ringel J, Erdmann K, Hampel S, et al., Carbon nanofibers and carbon nanotubes sensitize prostate and bladder cancer cells to platinum-based chemotherapeutics. J Biomed Nanotechnol 2014; 10: 463-77.
45. Lee SCJS, Lee JM, Jang A, et al., Effect of irradiation on total phenol and catechins contents and radical scavenging activity of green tea leaf and stem extract. J Food Biochem 2008; 32: 782-94.
46. Kerr CL, Hussain A., Regulators of prostate cancer stem cells. Curr Opin Oncol 2014; 26: 328-333.
47. Bisson I, Prowse DM., WNT signaling regulates self-renewal and differentiation of prostate cancer cells with stem cell characteristics. Cell Res 2009; 19: 683-97.
48. Singh A, Settleman J., EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010; 29: 4741-51.
49. Adhami VM, Ahmad N, Mukhtar H., Molecular targets for green tea in prostate cancer prevention. J Nutr 2003; 133 (7 Suppl): 2417S-24S.
50. Kuzuhara T, Sei Y, Yamaguchi K, et al., DNA and RNA as new binding targets of green tea catechins. J Biol Chem 2006; 281: 17446-56.
51. Park S, Choi J., Inhibition of beta-catenin/tcf signaling by flavonoids. J Cell Biochem 2010; 110: 1376-85.
52. Iftikhar H, Rashid S., Molecular docking studies of flavonoids for their inhibition pattern against beta-catenin and pharmacophore model generation from experimentally known flavonoids to fabricate more potent inhibitors for wnt signaling pathway. Pharm Mag 2014; 10 (Suppl 2): S264-71.
53. McLaughlin N, Annabi B, Lachambre MP, et al., Combined low dose ionizing radiation and green tea-derived epigallocatechin-3-gallate treatment induces human brain endothelial cells death. J Neuro-Oncol 2006; 80: 111-21.
54. McLaughlin N, Annabi B, Bouzeghrane M, et al., The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate. Brain Res 2006; 1071: 1-9.
55. Zhang S, Wang L, Liu H, et al., Enhancement of recombinant myricetin on the radiosensitivity of lung cancer a549 and h1299 cells. Diagn Pathol 2014; 9: 68.
56. Haley B, Frenkel E., Nanoparticles for drug delivery in cancer treatment. Urol Oncol 2008; 26: 57-64.
57. Tse BW, Cowin GJ, Soekmadji C, et al., PSMA-targeting iron oxide magnetic nanoparticles enhance MRI of preclinical prostate cancer. Nanomedicine 2015; 10: 375-86.
58. Dubrovska A, Kim C, Elliott J, et al., A chemically induced vaccine strategy for prostate cancer. ACS Chem Biol 2011; 6: 1223-31.